Shots: The P-ll RESTORE-1 study involves assessing NBIb-1817(VY-AADC) for the treatment of Parkinson’s disease. Neurocrine & Voyager will closely work with FDA & DCMB to determine the next clinical trial for RESTORE-1 DSMB request a clinical hold, follows the IND Safety Report submit by Neurocrine Biosciences related to the observation of MRI abnormalities in some […]Read More
Shots: The company highlights its lead candidate, SLN360 for CV disease associated with high Lp (a) levels and has received the US FDA’s IND approval to start dose-escalation studies in healthy volunteers and secondary prevention patients with elevated Lp(a). The company plans to start dosing healthy volunteers in the P-I study later this year The […]Read More
Shots: Amgen anticipates no disruption in its supply of medicines for patients across the globe due to COVID-19 and is expected to have no shortage of its therapies The company has temporarily paused the enrollment/screening in clinical studies to ensure the safety of subjects or integrity of data during a pandemic Amgen reported that P-II […]Read More
Shots: Medopod’s RPM platform will be available for NHS Trusts across the UK as well as global healthcare providers that allow doctors to track patient’s data, symptom progression and flag patients with worsening symptoms, both inside and outside of clinical settings Patients will use the app to share their personal data such as temperature, respiration […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
